Skip to main content
. 2020 Aug 28;72(9):1435–1446. doi: 10.1002/art.41275

Figure 3.

Figure 3

Changes in immunoglobulin and autoantibody levels in patients with rheumatoid arthritis with an inadequate response to methotrexate treated with placebo (PBO), fenebrutinib (FEN) 50 mg once daily (QD), fenebrutinib 150 mg once daily, fenebrutinib 200 mg twice daily (BID), or adalimumab (ADA) (cohort 1). A and B, Absolute change from baseline to week 12 in levels of total IgM (A) and IgG (B). C and D, Percent change from baseline to week 12 in levels of rheumatoid factor (RF) (C) and anti–citrullinated protein antibody (ACPA) (D). RF and ACPA analyses included patients who were positive at screening. Values are the median and interquartile range. * = P < 0.05 versus placebo.